

| Voclosporin Phase 3 Development Timelines | | 2011 | | | | 2012 | | | | 2013 | | | | 2014 | | | | 2015 | | | | |
|---|------------------------------------|------|----|----|----|------|----|----|----|------|----|----|----|------|----|----|----|------|----|----|----|--|
| | | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | |
| DRUG SUPPLY | Placed order for API at Lonza | | ■ | | | | | | | | | | | | | | | | | | | |
| | API to be manufactured by Lonza | | | | | ■ | ■ | | | | | | | | | | | | | | | |
| | API encapsulation | | | | | | ■ | ■ | | | | | | | | | | | | | | |
| | Packaged capsules shipped to sites | | | | | | | ■ | | | | | | | | | | | | | | |
| REGULATORY | Received EMA Scientific Advice | | | ■ | | | | | | | | | | | | | | | | | | |
| | Expect SPA approval from FDA | | | ■ | ■ | | | | | | | | | | | | | | | | | |
| | IND filed and accepted | | | | | ■ | ■ | | | | | | | | | | | | | | | |
| CLINICAL | 75 Clinical trial sites on-line | | | | | | ■ | | | | | | | | | | | | | | | |
| | First Patient First Visit (FPFV) | | | | | | ■ | | | | | | | | | | | | | | | |
| | Enrollment updates (18 months) | | | | | | ■ | ■ | ■ | ■ | ■ | ■ | ■ | | | | | | | | | |
| | Final patient starts dosing | | | | | | | | | | | | | ■ | | | | | | | | |
| | Last Patient Last Visit (LPLV) | | | | | | | | | | | | | | | | | | ■ | | | |
| | Data available | | | | | | | | | | | | | | | | | | | ■ | ■ | |